JAGXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Jaguar Health, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 19, 2026
$2.82−0.71 (-20.00%)
Close on Oct 19, 2026
- Market cap
- $2.28M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$1,089.18 (−99.74%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.EarningsSplit
Jaguar Health, Inc. grew revenue 135.5% to $27.82M over the twelve months to Jun 30, 2026.
Revenue
$27.82M
+135.5% vs. a year earlier
Operating income
-$25.90M
TTM Q2 2026
EPS, diluted
-$22.97
FY2025
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $2.28M
- P/E ratio
- –
- Price to sales
- 0.08
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Revenue
- $27.82M
- Net income
- -$53.58M
- EPS, diluted
- -$22.97
- Diluted shares
- 1M
Thirteen years at a glance
Fiscal years 2013 to 2025 and trailing twelve months, USD
Revenue
$27.82M+135.5% YoY
Gross profit
$22.89M+136.8% YoY
Operating income
-$25.90M
Net income
–
EPS, diluted
–
Free cash flow
–
Reported periodTrailing twelve months